FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry, particularly to antibodies specifically bound to epidermal growth factor receptors (EGFR), as well as to DNA coding V heavy chain regions of the above antibodies, to DNA coding V light chain regions of the above antibodies. There are disclosed expression vectors containing these DNAs, and animal cell lines for expression of the above antibodies containing these vectors. There are described compositions for treating cancer related to epidermal growth factor receptor (EGFR) containing an effective amount of the above antibodies.
EFFECT: invention enables treating cancer related to epidermal growth factor receptor (EGFR) effectively.
30 cl, 12 dwg, 12 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATITIS B VIRUS SURFACE ANTIGEN EPITOPE AND USE THEREOF | 2011 |
|
RU2585525C2 |
| EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF | 2013 |
|
RU2650770C2 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| RECOMBINANT YEAST TRANSFORMANT AND METHOD FOR OBTAINING WITH ITS USE OF Fc-FRAGMENT OF IMMUNOGLOBULIN | 2014 |
|
RU2664862C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
